The next generation in online publishing...
Sign up to read the digital versions of Managed Care, P&T, and Biotechnology Healthcare. These digital editions are free, searchable, and can be downloaded and read offline. To read a sample of the digital version of Managed Care, follow this link:
Sample digital edition
Register for a free digital subscriptionArchive issues of Managed Care:
MANAGED CARE August 2001. ©MediMedia USA
NEWS AND COMMENTARY
Controversy Swirls Over Unregulated RU-486 Print Ads
The National Abortion Federation, a professional association representing abortion providers in the U.S. and Canada, predicts that its advertising campaign for mifepristone that begin running in 13 national magazines last month will reach more than 70 percent of women under age 50. But because the ad is not sponsored by a drug manufacturer, the Food and Drug Administration did not need to review it for fair balance between effectiveness and risk information.
The ad gives the new drug's name, but fails to report information about possible side effects, contraindications, or efficacy. The ad claims the drug is a "medical breakthrough" that "safely and effectively terminates a pregnancy." NAF's executive director views the ad as a public service, as opposed to being a "pharmaceutical ad" — and thus believes FDA involvement isn't appropriate.
The product, which is covered by most health plans that cover surgical abortion, costs about $500.